Nasdaq20d
Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook - Update
(RTTNews) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal 2025 forecast.
C&EN28d
Role of the Capping Ligand in CsPbBr
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.
C&EN1mon
OpenMMDL - Simplifying the Complex: Building, Simulating, and Analyzing Protein–Ligand Systems in OpenMM
Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Molecular Design Group, Königin-Luisestr. 2 + 4, 14195 Berlin, Germany Department of Biology, Chemistry and Pharmacy, Institute of ...
SciELO1mon
SYNTHESIS, CHARACTERIZATION AND ANTIMICROBIAL ACTIVITY OF RUTHENIUM NITROSYL COMPLEXES CONTAINING POLYPYRIDYL LIGANDS
The most intense band at 265 nm arises from HOMO−3 to LUMO+4 transition. These MO are localized on the phen ligand. The shoulder at ca. 294 nm results from HOMO−2 to LUMO+2 transition associated with ...
Wall Street Journal4y
Ligand Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...